IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11654131 B1

PDFFull Text
Date of Patent:
May. 23, 2023

Filed:

Oct. 17, 2022

Composition and method of treatment of health issues related to estrogen metabolism with elevated risk factors in females

Applicant:

Matthias W Rath, Henderson, NV (US);

Inventors:

Aleksandra Niedzwiecki, Henderson, NV (US);

Matthias W Rath, Henderson, NV (US);

Parthena Boulikas, Sanjose, CA (US);

Anna Goc, Sanjose, CA (US);

Gabriela Lopez, Oakland, CA (US);

Assignee:

Other;

Attorneys:

Geeta Kadambi

Riddhi IP LLC

Primary Examiner:

Jessica Worsham

Int. Cl.
CPC ...
A61K 31/375 (2006.01); A61P 35/00 (2006.01); A61K 31/355 (2006.01); A61K 31/197 (2006.01); A61K 31/675 (2006.01); A61K 31/519 (2006.01); A61K 33/18 (2006.01); A61K 33/04 (2006.01); A61K 31/14 (2006.01); A61K 31/047 (2006.01); A61K 31/685 (2006.01); A61K 31/353 (2006.01); A61K 36/48 (2006.01); A61K 36/537 (2006.01); A61K 36/53 (2006.01); A23L 33/15 (2016.01); A23L 33/16 (2016.01); A23L 33/125 (2016.01); A23L 33/105 (2016.01); A61P 5/24 (2006.01);
U.S. Cl.
CPC ...
A61K 31/375 (2013.01); A23L 33/105 (2016.08); A23L 33/125 (2016.08); A23L 33/15 (2016.08); A23L 33/16 (2016.08); A61K 31/047 (2013.01); A61K 31/14 (2013.01); A61K 31/197 (2013.01); A61K 31/353 (2013.01); A61K 31/355 (2013.01); A61K 31/519 (2013.01); A61K 31/675 (2013.01); A61K 31/685 (2013.01); A61K 33/04 (2013.01); A61K 33/18 (2013.01); A61K 36/48 (2013.01); A61K 36/53 (2013.01); A61K 36/537 (2013.01); A61P 5/24 (2018.01); A61P 35/00 (2018.01); A23V 2002/00 (2013.01);
Abstract

A basic mix or Mix 1 or Mix 2 is highly effective in treating estrogen related complications in females. The estrogen related diseases such as cancer are also treated if they are Apo E based manifestations. The basic mix or Mix 1 or Mix 2 comprises of a combination of a Vitamin C (Ca ascorbate) 10 mg-100,000 mg, Vitamin E (D-alpha-tocopherol) 1-3,000 mg, Vitamin B5 1-20,000 mg, Vitamin B6 1-1,000 mg, Folic acid 1-3,000 mcg, Iodine (Kelp) 1-2,000 mcg, Selenium 1-2,000 mcg, Choline 1-5,000 mg, Inositol 1-5000 mg, Phosphatidyl serine 1-1,500 mg, Daidzein 1-1,500 mg, Glycitein 0.1-1,000 mg, Genistein 1-2,500 mg, Red clover 1-1,500 mg, Rosemary extract 1-6,000 mg and Chaste tree berry (-castus) 1-2,000 mg. The treatment by administering Mix 1 decreases estrogen dependent breast cancer cells proliferation and decrease in expression of cancer promoting cellular markers in cancer cells (iNOS, ApoE).

Find Patent Forward Citations

Loading…